Sutro Biopharma (NASDAQ:STRO) Raised to Overweight at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, MarketBeat.com reports. The firm currently has a $2.00 target price on the stock. Piper Sandler’s target price would indicate a potential upside of […]
Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, MarketBeat.com reports. The firm currently has a $2.00 target price on the stock. Piper Sandler’s target price would indicate a potential upside of […]
